AU3328499A - Phthalazinone pde iii/iv inhibitors - Google Patents

Phthalazinone pde iii/iv inhibitors

Info

Publication number
AU3328499A
AU3328499A AU33284/99A AU3328499A AU3328499A AU 3328499 A AU3328499 A AU 3328499A AU 33284/99 A AU33284/99 A AU 33284/99A AU 3328499 A AU3328499 A AU 3328499A AU 3328499 A AU3328499 A AU 3328499A
Authority
AU
Australia
Prior art keywords
phthalazinone
inhibitors
pde iii
pde
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33284/99A
Other languages
English (en)
Inventor
Rolf Beume
Hildegard Boss
Dietrich Hafner
Armin Hatzelmann
Hans-Peter Kley
Geert Jan Sterk
Hendrik Timmerman
Ivonne Johanna Van Der Laan
Margaretha Van Der Mey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Byk Gulden Lomberg Chemische Fabrik GmbH
Publication of AU3328499A publication Critical patent/AU3328499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU33284/99A 1998-03-14 1999-03-04 Phthalazinone pde iii/iv inhibitors Abandoned AU3328499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98104643 1998-03-14
EP98104643 1998-03-14
PCT/EP1999/001413 WO1999047505A1 (en) 1998-03-14 1999-03-04 Phthalazinone pde iii/iv inhibitors

Publications (1)

Publication Number Publication Date
AU3328499A true AU3328499A (en) 1999-10-11

Family

ID=8231589

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33284/99A Abandoned AU3328499A (en) 1998-03-14 1999-03-04 Phthalazinone pde iii/iv inhibitors

Country Status (12)

Country Link
US (1) US6255303B1 (enExample)
EP (1) EP1070056B1 (enExample)
JP (1) JP2002506856A (enExample)
AT (1) ATE270278T1 (enExample)
AU (1) AU3328499A (enExample)
CA (1) CA2323771A1 (enExample)
DE (1) DE69918422T2 (enExample)
DK (1) DK1070056T3 (enExample)
ES (1) ES2224628T3 (enExample)
PT (1) PT1070056E (enExample)
SI (1) SI1070056T1 (enExample)
WO (1) WO1999047505A1 (enExample)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO2001019818A1 (en) * 1999-09-14 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone derivatives as pd3/4 inhibitors
CN1146562C (zh) 1999-10-25 2004-04-21 奥坦纳医药公司 作为pde4抑制剂的四氢噻喃2,3-二氮杂萘酮类衍生物
DE60036558D1 (de) 1999-10-25 2007-11-08 Nycomed Gmbh Phthalazinon-derivate als pde 4 hemmer
AU7576001A (en) 2000-08-05 2002-02-18 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP4301812B2 (ja) * 2001-02-15 2009-07-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしてのフタラインオン−ピペリジノ−誘導体
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
AU2002317733B2 (en) 2001-04-25 2007-12-13 Altana Pharma Ag Phthalazinones derivatives useful as PDE4/7 inhibitors
PL363544A1 (en) 2001-04-25 2004-11-29 Altana Pharma Ag Piperazino-derivatives and their use as pde4 inhibitor
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
WO2003008396A1 (en) * 2001-07-16 2003-01-30 Nikken Chemicals Co., Ltd. Optically active oxazine derivative
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
CA2458534C (en) 2001-09-14 2011-11-01 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
JP2005523920A (ja) 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
WO2004018449A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
WO2004017974A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors
CA2494650A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
HRP20050197A2 (en) * 2002-08-10 2006-06-30 Altana Pharma Ag Piperidine-n-oxide-derivatives
DK1556342T3 (da) 2002-10-28 2008-07-21 Glaxo Group Ltd Phenethanolaminderivat til behandling af respiratoriske sygdomme
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
US20080227790A1 (en) * 2004-02-04 2008-09-18 Altana Pharma Ag Pyridazinone Derivatives and their Use as Pde4 Inhibitors
CA2554797C (en) * 2004-02-04 2012-09-04 Altana Pharma Ag 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2006072599A2 (en) 2005-01-10 2006-07-13 Glaxo Group Limited Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
AR060536A1 (es) 2006-04-20 2008-06-25 Glaxo Group Ltd Agonista del receptor de glucocorticoides y composiciones farmaceuticas
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
NZ574873A (en) 2006-07-25 2012-03-30 Cephalon Inc Pyridazinone derivatives as h3 inhibitors
JPWO2008111631A1 (ja) * 2007-03-14 2010-06-24 日本新薬株式会社 α−メチルベンジルアミン塩の製法
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
US20110160249A1 (en) 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
CA2728016C (en) * 2008-06-24 2017-02-28 F. Hoffmann-La Roche Ag Novel substituted pyridin-2-ones and pyridazin-3-ones
PT2300459E (pt) * 2008-07-02 2013-07-04 Hoffmann La Roche Novas fenilpirazinonas utilizadas como inibidores de cinase
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
CA2755773A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
JP2012520685A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520686A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012521763A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子１（ＳＴＡＴ１）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20110138223A (ko) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
UY32571A (es) 2009-04-24 2010-11-30 Glaxo Group Ltd Compuestos derivados de pirazol amida
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
TWI516487B (zh) 2009-04-30 2016-01-11 葛蘭素集團有限公司 新穎化合物、其醫藥組合物及作為激酶活性抑制劑之用途
PL2453894T3 (pl) 2009-07-15 2016-04-29 Theravance Biopharma R&D Ip Llc Postać krystaliczna wolnej zasady związku bifenylowego
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
EP3020393B1 (en) 2009-12-16 2020-10-07 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
PL2614058T3 (pl) 2010-09-08 2015-12-31 Glaxosmithkline Ip Dev Ltd Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
WO2012052458A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
US9149462B2 (en) 2010-10-21 2015-10-06 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
JP5980318B2 (ja) * 2011-06-17 2016-08-31 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 新規のフタラジノン−ピロロピリミジンカルボキサミド誘導体
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014160440A1 (en) 2013-03-13 2014-10-02 Flatley Discovery Lab Pyridazinone compounds and methods for the treatment of cystic fibrosis
WO2014159776A1 (en) * 2013-03-14 2014-10-02 Cephalon, Inc. Solid state forms of 6-[4-[3-(r)-2-methylpyrrolidine-1-yl)-propoxy]phenyl]2h-pyridazine-3-one hydrochloride
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CA2925064A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
KR101891933B1 (ko) 2014-08-14 2018-08-24 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 피리다존 및 트라이아진온
CN104478809B (zh) * 2014-11-14 2016-08-17 成都新恒创药业有限公司 一种左西孟旦杂质及其制备和检测方法
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
WO2018094392A1 (en) 2016-11-21 2018-05-24 Lupin Inc. Medicament dispenser
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2019195711A1 (en) 2018-04-06 2019-10-10 Lupin Inc. Medicament dispenser
WO2020058823A1 (en) 2018-09-17 2020-03-26 Lupin, Inc. Dose indicator assembly for a medicament dispenser
WO2021195353A1 (en) 2020-03-25 2021-09-30 Lupin Inc. Multi-carrier medicament dispensers
US20230270956A1 (en) 2020-07-23 2023-08-31 Lupin Inc. Dose counter assemblies for medicament dispensers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58116471A (ja) * 1981-12-29 1983-07-11 Nippon Kayaku Co Ltd ４−ヒドロキシメチル−１−フタラゾンエステル誘導体およびその塩
AU673569B2 (en) * 1992-12-02 1996-11-14 Pfizer Inc. Catechol diethers as selective PDE-IV inhibitors
EP0634404A1 (en) * 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Phtalazin derivatives and their use as pesticides
DE19533975A1 (de) * 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
DE69811645T2 (de) * 1997-01-15 2003-12-04 Altana Pharma Ag Phtalazinonen

Also Published As

Publication number Publication date
ATE270278T1 (de) 2004-07-15
ES2224628T3 (es) 2005-03-01
DK1070056T3 (da) 2004-11-08
US6255303B1 (en) 2001-07-03
JP2002506856A (ja) 2002-03-05
EP1070056A1 (en) 2001-01-24
EP1070056B1 (en) 2004-06-30
DE69918422T2 (de) 2005-08-11
WO1999047505A1 (en) 1999-09-23
PT1070056E (pt) 2004-11-30
DE69918422D1 (de) 2004-08-05
CA2323771A1 (en) 1999-09-23
SI1070056T1 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
AU3328499A (en) Phthalazinone pde iii/iv inhibitors
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
CA2297911A1 (en) Substituted 6-phenylphenanthridines
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
UA74370C2 (uk) Піроло(2,3-d)піримідинові сполуки як імуносупресори
WO2002085906A3 (en) Phthalazinones derivatives useful as pde4/7 inhibitors
AU5414000A (en) Compounds
MXPA03008754A (es) Derivados de piridina fundidos para utilizarse como agonistas receptores vaniloide para tratar dolor.
AU2291097A (en) Novel phenanthridines substituted in the 6 position
AU1782301A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
PL341239A1 (en) Dihydrobenzofuranes
HK1047276A1 (zh) 作为pde4抑制剂的四氢噻喃2，3-二氮杂萘酮类衍生物
AU2289400A (en) 6-arylphenanthridines with pde-iv inhibiting activity
AU1781601A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
SI1377574T1 (enExample)
AU7027100A (en) Novel compounds
AU4714297A (en) Metalloproteinase inhibitors
ATE374189T1 (de) Phthalazinon-derivate als pde 4 hemmer
AP2001002045A0 (en) FKBP inhibitors.
DE60011677D1 (en) Tryptase-inhibitoren
SI1244614T1 (en) Tryptase inhibitors
WO2000043375A3 (de) Substituierte arylheterocyclen
MY133140A (en) N-substituted azabicycloheptane derivatives, their preparation and use
AU6629000A (en) Novel hypoxanthine and thiohypoxanthine compounds
IL169334A0 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase